SYT-510, the Clinical Candidate of First-in-class Selective Endocannabinoid Reuptake Inhibitors, Demonstrated Efficacy in Preclinical Models of Anxiety, Spasticity, Seizure, Pain and Neuroinflammation

Establishing Primary Structure Comparability Between ABP-450 (probotulinumtoxinA) and OnabotulinumtoxinA (Botox®) to Support Biosimilarity

Baclofen Toxicity Presenting as Generalized Myoclonus and Choreoathetosis Without Altered Consciousness in the Setting of Acute-on-chronic Kidney Disease